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Figure 1
5-Year Follow-Up Patient Flow Chart of the
Nordic Bifurcation Study
*A total of 307 patients had a quantitative coronary assessment at the index
procedure and after 8 months. MV ¼ main vessel; SB ¼ side branch.
Abbreviations
and Acronyms
CABG = coronary artery
bypass graft operation
DES = drug-eluting stents
MACE = major adverse
cardiac events
MI = myocardial infarction
MV = main vessel
PCI = percutaneous coronary
intervention
SB = side branch
ST = stent thrombosis
TLR = target lesion
revascularization
TVR = target vessel
revascularization
JACC Vol. 62, No. 1, 2013 Maeng et al.
July 2, 2013:30–4 Simple Versus Complex Bifurcation Stenting
31Using drug-eluting stents (DES) in coronary bifurcation
lesions, the simple strategy of main vessel (MV) and optional
side branch (SB) stenting has been compared to the more
complex strategy of planned stenting of the MV and SB in
a number of randomized studies with short-term follow-up
(1–5). The general finding was that the optional SB stenting
strategy resulted in comparable or better clinical outcomes,
and was associated with shorter procedure and fluoro-
scopy times, and less use of contrast. Therefore, optional
SB stenting has become the recommended bifurcation
treatment strategy.
In percutaneous coronary intervention (PCI), long-term
clinical results are the ultimate assessment of different
treatment modalities or devices (6,7). The present paper
supplements our current knowledge on the short-term
results of optional SB stenting versus MV plus SB stent-
ing by presenting the 5-year clinical outcomes of the Nordic
Bifurcation Study.
Methods
Patients and study design. This nonblinded randomized
multicenter trial (NCT00376571) was conducted at 28
cardiology centers in Denmark, Sweden, Finland, Norway,
and Latvia. The 413 patients were included from September
2004 to May 2005. The protocol was approved by ethics
committees in all participating countries, and all partici-
pating patients gave written informed consent. The design
of the Nordic Bifurcation Study has been published (1). In
short, patients with stable, unstable, or silent angina pectoris
and a de novo coronary bifurcation lesion were included.
Diameter of the MV should be 2.5 mm and diameter of
the SB 2.0 mm by visual estimate.
The sirolimus-eluting Cypher Selectþ stent (Cordis,
Johnson & Johnson, Bridgewater, New Jersey) was used in
the study. The study lesion was pre-dilated and/or post-
dilated at the discretion of the operator. In the optional
SB stenting group, the main treatment principles were as
follows: 1) stenting of MV; 2) SB dilation if SB TIMI
(Thrombolysis In Myocardial Infarction) flow grade <3; and
3) SB stenting if SB TIMI flow was 0 after dilation. In the
stenting of the MV and the SB group, the main treatment
principles were: 1) stenting of both the MV and SB applying
the “crush technique” (8), “culotte technique” (9), or other
techniques at the discretion of the operator; and 2) in all
cases of SB stenting, the protocol required a “kissing
balloon” dilation at the end of the procedure. The recom-
mended clopidogrel treatment time was 6 to 12 months.
Five-year follow-up. Data on total death, cardiac death,
myocardial infarction (MI), target lesion revascularization
(TLR), target vessel revascularization (TVR), and angio-
graphically verified definite stent thrombosis (ST) were
obtained by yearly clinical control visits or telephone
contacts to the patients. National registries and hospital files
were used in case of death or admission to the hospital for
a suspected cardiac event.Study endpoints. We used the
endpoint definitions reported in
the primary publication (1). End-
points were all-cause death, car-
diac death, non–procedure-related
MI, TLR, TVR, ST, and the
combined endpoint of cardiac
death, non–procedure-relatedMI,
TVR by PCI or coronary artery
bypass graft surgery (CABG), and
ST. The endpoints up to 3 years
were adjudicated blindly by an
independent endpoint committee.
Endpoints from 3 to 5 years were
evaluated independently by 2
researchers (M.M. and N.R.H.).
In case of discrepancies, consen-
sus was obtained between the 2
researchers and a third senior in-
terventional cardiologist (L.T.).
Statistical analysis. Differences in categorical variables
between the 2 groups were analyzed using the chi-square test
or Fisher exact test. Continuous variables were analyzed
using Student t test or Mann-Whitney U test, and time-to-
event data using the Kaplan-Meier method and the log-rank
test. All p values were 2-sided. Level of significance was 5%.
The analysis was performed on an intention-to-treat basis.
All analyses were performed using Stata version 12 (Stata-
Corp, College Station, Texas).Results
A total of 413 patients were included in the study. Five-year
clinical follow-up data were available for 404 (98%) patients,
202 in the MV group, and 202 in the MV plus SB group.
Table 1
Baseline Clinical Characteristics of 5-Year Follow-Up
Cohort of the Nordic Bifurcation Study
MV
(n ¼ 202)
MVþSB
(n ¼ 202) p Value
Age, yrs 63  10 63  10 0.49
Male 76 78 0.63
Indication
Stable angina pectoris 66 65
Unstable angina pectoris 32 34
Silent ischemia 2 1
Vessel treated
Left anterior descending artery 73 74
Circumflex artery 17 18
Right coronary artery 7 6
Left main 2 1
Diabetes mellitus 13 12 0.65
Hypercholesterolemia 78 72 0.14
Hypertension 54 58 0.42
Family history 58 54 0.59
Prior PCI 25 25 1.00
Prior CABG 4 3 0.58
Aspirin 99.5 98.5 0.32
Clopidogrel 100 99.5 0.31
Glycoprotein IIb/IIIa inhibitors 51 51 0.92
Values are mean  SD or %.
CABG ¼ coronary artery bypass graft surgery; MV ¼ main vessel; PCI ¼ percutaneous coronary
intervention; SB ¼ side branch; SD ¼ standard deviation.
Table 3
Clinical Endpoints at 5-Year Follow-Up of the
Nordic Bifurcation Study
MV MVþSB p Value
All-cause death 5.9 10.4 0.16
Cardiac death 2.5 4.0 0.40
Myocardial infarction 4.0 7.9 0.09
Target lesion revascularization 11.3 15.3 0.24
Target vessel revascularization 13.4 18.3 0.14
Target vessel revascularization by CABG 2.0 3.5 0.38
Stent thrombosis* 3.0 1.5 0.32
Values are %. *Angiographically verified stent thrombosis.
Abbreviations as in Table 1.
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32Eight patients were lost to follow-up, and 1 patient with-
drew consent. Figure 1 shows the patient flow diagram.
The 2 groups were well balanced regarding baseline
clinical variables (Table 1) and procedural characteristics
(Table 2). There was no significant difference between theTable 2
Procedural Characteristics of 5-Year Follow-Up
Cohort of the Nordic Bifurcation Study
MV
(n ¼ 202)
MVþSB
(n ¼ 202) p Value
Median lesion length*
MV, mm 16 (12–24) 16 (12–20) 0.76
SB, mm 5 (3–8) 5 (4–8) 0.15
Median stent length
MV, mm 23 (18–28) 23 (18–28) 0.89
Reference diameter,*
proximal
MV, mm 3.3  0.4 3.3  0.4 0.91
SB, mm 2.6  0.6 2.6  0.3 0.98
True bifurcation lesion 77 67 0.026
Angulation <70 63 66 0.46
Visible calcification 60 47 0.14
Tortuous proximal vessel 4 8 0.09
MV stented 99.5 98.5 0.37
SB stented 4.4 95.0 <0.0001
Final kissing balloon 32 74 <0.0001
Procedural success 97 94 0.24
Procedure time, min 55 (35–75) 70 (55–90) <0.0001
Fluoroscopy time, min 13 (9–20) 19 (14–26) <0.0001
Contrast volume, ml 210 (160–280) 265 (200–330) <0.0001
Values are % (interquartile range), mean  1 SD or %. *Visual assessment.
Abbreviations as in Table 1.2 groups with respect to vessel size or severity of stenosis
as assessed by the operator. Genuine bifurcations were
more prevalent in the MV group, whereas the bifurcation
lesion characteristics of SB angulation <70, vessel
calcification, and proximal vessel tortuosity were evenly
distributed.
Five-year clinical outcomes are presented in Table 3. The
rates of the efficacy parameters, TLR and TVR, were nu-
merically lower in the MV group, but the differences were
not statistically different. The safety parameters, all-cause
death, cardiac death, and ST did not differ significantly
between the 2 groups. Angiographically verified ST occurred
in 6 patients in the MV group (3% [acute, n ¼ 0; subacute,
n ¼ 1; late, n ¼ 3; and very late, n ¼ 2]), and in 3 patients in
the MV plus SB group (1.5% [acute, n ¼ 0; subacute, n ¼ 0;
late, n ¼ 1; and very late, n ¼ 2]).
The Kaplan-Meier curves for major adverse cardiac events
(MACE)-free survival did not differ significantly between the
groups, with the 5-year MACE-free survival being 84.2% in
the MV group versus 78.2% in the MV plus SB group (p ¼
0.12) (Fig. 2A).
Including total death in a post-hoc MACE analysis
(all-cause death, non–procedure-related MI and TVR),
event-free survival rates were 81.7% in the MV group versus
71.8% in the MV plus SB groups (p ¼ 0.03) (Fig. 2B). In
patients with genuine “true” bifurcation lesions, MACE
rates were 19.9% versus 30.1% (p ¼ 0.044) in the MV
versus the MV plus SB group.Discussion
This is the first publication of long-term follow-up data
from a randomized comparison of coronary bifurcation
treatment strategies comparing the simple strategy of MV
stenting plus optional SB stenting versus the more complex
planned stenting of MV plus SB. We found no significant
differences regarding clinical safety and efficacy in the
2 study groups, although a trend toward superior results in
patients treated with the simple strategy was observed.
Coronary bifurcations represent a challenging lesion
subset. Balloon angioplasty of bifurcation lesions was
associated with poor results, and restenosis frequently
complicated bare-metal stent implantation, especially if
Figure 2 MACE-Free Survival at 5-Year Follow-Up
(A) The primary endpoint of major adverse cardiac events (MACE), defined as
cardiac death, non–percutaneous coronary intervention (PCI)-related myocardial
infarction (MI), target vessel revascularization (TVR), and stent thrombosis (ST).
(B) A post-hoc analysis defining MACE as all-cause death, non–PCI-related MI,
TVR, and ST. The blue lines represent the simple MV plus optional SB stenting; the
red lines represent the complex 2-stent MV plus SB stenting strategy. MV ¼ main
vessel; non-proc ¼ non-procedure; SB ¼ side branch.
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332 stent techniques were used (10,11). DES treatment
gave rise to optimistic reports on low rates of acute events
and minimal problems with restenosis (12). Later, a high
rate of ST was reported in complex coronary lesions,
especially in bifurcations (13,14). The potential high risk
of ST was a concern when we designed the Nordic
Bifurcation Study because multiple layers of stents,
deformation of stent architecture, stent strut malap-
position, and SB stent jail were thought to predispose to
early and late thrombotic events. Such architectural
changes were likely to be more pronounced after the
complex MV and SB stenting using culotte, crush, or T
techniques. After 5 years, the rates of ST, cardiac death,
all-cause death, and non–procedure-related MI were
similar in the 2 treatment groups, albeit numerically
greater after the use of MV plus SB stenting with the
exception of ST. Thus, our data demonstrate a highdegree of long-term safety irrespective of the bifurcation
stenting strategy used, but do support the simple bifur-
cation strategy whenever feasible.
Although the Kaplan-Meier curves of the combined
safety and efficacy endpoint (MACE) separated over time,
showing an absolute 6% difference in favor of the simple
strategy at 5-year follow-up, this difference was not statis-
tically different. However, a post-hoc analysis, substituting
cardiac death with all-cause death in the MACE analysis,
resulted in significantly more events in the MV plus SB
group and added further support to the simple MV stenting
plus optional SB stenting approach. Using all-cause death
instead of cardiac death may be relevant, as late-occurring
fatal events in elderly patients may be difficult to classify
correctly.
Study limitations. First, only 72% of the patients had
a genuine bifurcation lesion with stenosis in both the MV
and the SB. However, even patients with genuine “true”
bifurcation lesions had significantly better outcomes when
treated with the simple approach. Second, the results in
the MV plus SB group may in part reflect a learning
curve in complex bifurcation stenting. In this first Nordic
Bifurcation Study, 74% of the patients treated with
a complex stenting strategy had final kissing balloon
dilation (1). In the Nordic Stent Technique Study, this
number had increased to 85% in the crush group and 92%
in the culotte group (15). Third, various 2-stent strategies
were used in the complex group. We have previously
shown that the crush technique approximately doubled
the risk of angiographic in-stent restenosis in comparison
to the culotte technique (10.5% vs. 4.5%, p ¼ 0.046),
although this observation did not impact MACE rates
(4.3% vs. 3.7%, p ¼ 0.87) (15). Although we did not find
major differences between the crush and the culotte
techniques, we cannot exclude the possibility that use of
the culotte technique, or another 2-stent strategy in the
majority of patients, could have had an impact on clinical
outcomes.
Conclusions
At the 5-year follow-up of the Nordic Bifurcation Study, the
clinical outcomes after simple MV plus optional SB stenting
remained at least equal to the more complex strategy of
stenting both the MV and the SB. The simple approach
thus remains the recommended bifurcation treatment
strategy.
Acknowledgments
The authors thank the study coordinators: Helle Bargsteen,
medical secretary, Pia Ottosen, RN, Lars Raballowich
Jørgensen, research coordinator. Data monitoring and safety:
members of the steering committee. Statistical support: Niels
Ramsing Holm, Aarhus University Hospital, Skejby,
Denmark. Clinical endpoint committee: Kristian Thygesen,
MD, Aarhus University Hospital, Aarhus, Denmark; Jan
Ravkilde, MD, Aarhus University Hospital, Aalborg,
Maeng et al. JACC Vol. 62, No. 1, 2013
Simple Versus Complex Bifurcation Stenting July 2, 2013:30–4
34Denmark; Kjell Nikus, MD, Tampere University Hospital,
Finland.
Reprint requests and correspondence: Dr. Michael Maeng,
Department of Cardiology, Aarhus University Hospital, Brend-
strupgaardsvej, Skejby, 8200 Aarhus N, Denmark. E-mail:
michael.maeng@ki.au.dk.
REFERENCES
1. Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple
versus complex stenting of coronary artery bifurcation lesions: the
Nordic bifurcation study. Circulation 2006;114:1955–61.
2. Ferenc M, Gick M, Kienzle RP, et al. Randomized trial on routine vs.
provisional T-stenting in the treatment of de novo coronary bifurcation
lesions. Eur Heart J 2008;29:2859–67.
3. Hildick-Smith D, De Belder AJ, Cooter N, et al. Randomized trial of
simple versus complex drug-eluting stenting for bifurcation lesions.
The British Bifurcation Coronary Study: old, new, and evolving
strategies. Circulation 2010;121:1235–43.
4. Colombo A, Bramucci E, Sacca S, et al. Randomized study of the crush
technique versus provisional side-branch stenting in true coronary
bifurcations: the CACTUS (Coronary Bifurcations: Application of the
Crushing Technique Using Sirolimus-Eluting Stents) study. Circula-
tion 2009;119:71–8.
5. Pan M, de Lezo JS, Medina A, et al. Rapamycin-eluting stents for
the treatment of bifurcated coronary lesions: a randomized com-
parison of a simple versus complex strategy. Am Heart J 2004;148:
857–64.
6. Maeng M, Tilsted HH, Jensen LO, et al. 3-Year clinical outcomes in
the randomized SORT OUT III superiority trial comparing zotar-
olimus- and sirolimus-eluting coronary stents. J Am Coll Cardiol Intv
2012;5:812–8.7. Stefanini GG, Kalesan B, Serruys PW, et al. Long-Term Clinical
Outcomes of Biodegradable Polymer Biolimus-Eluting Stents
Versus Durable Polymer Sirolimus-Eluting Stents in Patients
With Coronary Artery Disease (LEADERS): 4-year follow-up of
a randomised non-inferiority trial. Lancet 2011;378:1940–8.
8. Colombo A, Stankovic G, Orlic D, et al. Modified T-stenting
technique with crushing for bifurcation lesions: immediate results and
30-day outcome. Catheter Cardiovasc Interv 2003;60:145–51.
9. Chevalier B, Glatt B, Royer T, Guyon P. Placement of coronary stents
in bifurcation lesions by the “culotte” technique. Am J Cardiol 1998;82:
943–9.
10. Pinkerton CA, Slack JD, van Tassel JW, Orr CM. Angioplasty for
dilation of complex coronary artery bifurcation stenoses. Am J Cardiol
1985;55:1626–8.
11. Al Suwaidi J, Yeh W, Cohen HA, Detre KM, Williams DO,
Holmes DR Jr. Immediate and 1-year outcome in patients with
coronary bifurcation lesions in the modern era (NHLBI dynamic
registry). Am J Cardiol 2001;87:1139–44.
12. Thuesen L, Kelbaek H, Klovgaard L, et al. Comparison of sirolimus-
eluting and bare metal stents in coronary bifurcation lesions:
subgroup analysis of the Stenting Coronary Arteries in Non-Stress/
Benestent Disease Trial (SCANDSTENT). Am Heart J 2006;152:
1140–5.
13. Colombo A, Moses JW, Morice MC, et al. Randomized study to
evaluate sirolimus-eluting stents implanted at coronary bifurcation
lesions. Circulation 2004;109:1244–9.
14. Hoye A, Iakovou I, Ge L, et al. Long-term outcomes after stenting of
bifurcation lesions with the “crush” technique: predictors of an adverse
outcome. J Am Coll Cardiol 2006;47:1949–58.
15. Erglis A, Kumsars I, Niemela M, et al. Randomized comparison of
coronary bifurcation stenting with the crush versus the culotte tech-
nique using sirolimus eluting stents: the Nordic Stent Technique Study.
Circ Cardiovasc Interv 2009;2:27–34.
Key Words: bifurcation - drug-eluting stent - randomized -
restenosis - stent thrombosis.
